{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:35:46Z","timestamp":1764729346017,"version":"3.46.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MUNI\/A\/1685\/2024","MUNI\/A\/1685\/2024","MUNI\/A\/1685\/2024"],"award-info":[{"award-number":["MUNI\/A\/1685\/2024","MUNI\/A\/1685\/2024","MUNI\/A\/1685\/2024"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06703-5","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T01:11:58Z","timestamp":1762305118000},"page":"6105-6108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Tom\u00e1\u0161","family":"Hor\u0148\u00e1k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"10","key":"6703_CR1","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG (2022) Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev 3(10):e674\u2013e689. https:\/\/doi.org\/10.1016\/S2666-7568(22)00186-6","journal-title":"Lancet Healthy Longev"},{"issue":"11","key":"6703_CR2","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 35(11):1763\u20131774. https:\/\/doi.org\/10.1007\/s12325-018-0805-y","journal-title":"Adv Ther"},{"issue":"11","key":"6703_CR3","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1002\/cncr.21907","volume":"106","author":"LS Elting","year":"2006","unstructured":"Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC (2006) Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106(11):2452\u20132458. https:\/\/doi.org\/10.1002\/cncr.21907","journal-title":"Cancer"},{"issue":"9405","key":"6703_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(03)15383-4","volume":"363","author":"JM Peppercorn","year":"2004","unstructured":"Peppercorn JM, Weeks JC, Cook EF, Joffe S (2004) Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363(9405):263\u2013270. https:\/\/doi.org\/10.1016\/S0140-6736(03)15383-4","journal-title":"Lancet"},{"issue":"3","key":"6703_CR5","doi-asserted-by":"publisher","first-page":"dju002","DOI":"10.1093\/jnci\/dju002","volume":"106","author":"JM Unger","year":"2014","unstructured":"Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R et al (2014) Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 106(3):dju002. https:\/\/doi.org\/10.1093\/jnci\/dju002","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6703_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00996-x","volume":"14","author":"IS Tiong","year":"2024","unstructured":"Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Australasian Leukaemia and Lymphoma Group (ALLG) et al (2024) How comparable are patient outcomes in the \u201creal-world\u201d with populations studied in pivotal AML trials? Blood Cancer J 14(1):54. https:\/\/doi.org\/10.1038\/s41408-024-00996-x","journal-title":"Blood Cancer J"},{"issue":"1","key":"6703_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2457809","volume":"30","author":"DS Bruno","year":"2025","unstructured":"Bruno DS, Khanal M, Li X, Escalon MP, Winfree K, Hess LM (2025) Clinical trial participation, clinical care, and patient outcomes by practice setting: a real-world database analysis of patients with chronic lymphocytic leukemia or mantle cell lymphoma. Hematology 30(1):2457809. https:\/\/doi.org\/10.1080\/16078454.2025.2457809","journal-title":"Hematology"},{"key":"6703_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.844779","volume":"12","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Bertuglia G, Oliva S (2022) Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results. Front Oncol 12:844779. https:\/\/doi.org\/10.3389\/fonc.2022.844779","journal-title":"Front Oncol"},{"issue":"6","key":"6703_CR9","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 29(6):1336\u20131343. https:\/\/doi.org\/10.1038\/leu.2015.73","journal-title":"Leukemia"},{"issue":"3","key":"6703_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/leu.2016.246","volume":"31","author":"VS Hoffmann","year":"2017","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF et al (2017) Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia 31(3):593\u2013601. https:\/\/doi.org\/10.1038\/leu.2016.246","journal-title":"Leukemia"},{"issue":"7","key":"6703_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","volume":"20","author":"A Makady","year":"2017","unstructured":"Makady A, de Boer A, Hillege H, Klungel O, Goettsch W (2017) What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health 20(7):858\u2013865. https:\/\/doi.org\/10.1016\/j.jval.2017.03.008","journal-title":"Value Health"},{"key":"6703_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100913","volume":"53","author":"BA Derman","year":"2022","unstructured":"Derman BA, Belli AJ, Battiwalla M, Hamadani M, Kansagra A, Lazarus HM et al (2022) Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. Blood Rev 53:100913. https:\/\/doi.org\/10.1016\/j.blre.2021.100913","journal-title":"Blood Rev"},{"issue":"23","key":"6703_CR13","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1182\/bloodadvances.2021005902","volume":"5","author":"WA Wood","year":"2021","unstructured":"Wood WA, Marks P, Plovnick RM, Hewitt K, Neuberg DS, Walters S, Dolan Brendan K., Tucker Emily A., Abrams Charles S., Thompson Alexis A., Anderson Kenneth C., Kluetz Paul, Farrell Ann, Rivera Donna, Gertzog Matthew, Pappas Gregory (2021) ASH research collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology. Blood Adv 5(23):5429\u20135438. https:\/\/doi.org\/10.1182\/bloodadvances.2021005902","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06703-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06703-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06703-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:30Z","timestamp":1764729090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06703-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":13,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6703"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06703-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by Ethics Committee of University Hospital Brno.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"TH served on a speaker\u2019s bureau for Novartis and received travel grant from Novartis and Angelini Pharma. D\u017d served as a member of advisory board for Novartis, Zentiva, Ascentage, Enliven Therapeutics, served on a speaker\u2019s bureau for Novartis and Angelini Pharma, served as a consultant for Novartis and Angelini Pharma. JM Received research support from Novartis and BMS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}